A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
Clinical trial NCT06936644 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06936644
- Sponsor
- Shanghai Chest Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-30
- Primary completion
- 2027-04-30
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.